Provectus Biopharmaceuticals Valuation
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceutica seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Provectus Biopharmaceutica from analyzing the company fundamentals such as Return On Asset of -1.85, shares owned by institutions of 0.04 %, and Shares Outstanding of 419.55 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors support acquiring undervalued entities and selling overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Provectus Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Provectus Biopharmaceutica is based on 3 months time horizon. Increasing Provectus Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Provectus Biopharmaceuticals is useful when determining the fair value of the Provectus otc stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Provectus Biopharmaceutica. Since Provectus Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Provectus OTC Stock. However, Provectus Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.11 | Real 0.0946 | Hype 0.11 | Naive 0.12 |
The real value of Provectus OTC Stock, also known as its intrinsic value, is the underlying worth of Provectus Biopharmaceutica OTC Stock, which is reflected in its stock price. It is based on Provectus Biopharmaceutica's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Provectus Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Provectus Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Provectus Biopharmaceuticals helps investors to forecast how Provectus otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Provectus Biopharmaceutica more accurately as focusing exclusively on Provectus Biopharmaceutica's fundamentals will not take into account other important factors: Provectus Biopharmaceutica Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Provectus Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Provectus Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Provectus Biopharmaceutica competition to find correlations between indicators driving Provectus Biopharmaceutica's intrinsic value. More Info.Provectus Biopharmaceuticals is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Provectus Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Provectus Biopharmaceutica's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Provectus Biopharmaceutica's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Provectus Biopharmaceutica's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Provectus Biopharmaceutica and how it compares across the competition.
About Provectus Biopharmaceutica Valuation
The otc valuation mechanism determines the current worth of Provectus Biopharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Provectus Biopharmaceuticals. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Provectus Biopharmaceutica based exclusively on its fundamental and basic technical indicators. By analyzing Provectus Biopharmaceutica's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Provectus Biopharmaceutica's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Provectus Biopharmaceutica. We calculate exposure to Provectus Biopharmaceutica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Provectus Biopharmaceutica's related companies.Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
8 Steps to conduct Provectus Biopharmaceutica's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Provectus Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Provectus Biopharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Provectus Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Provectus Biopharmaceutica's revenue streams: Identify Provectus Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Provectus Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Provectus Biopharmaceutica's growth potential: Evaluate Provectus Biopharmaceutica's management, business model, and growth potential.
- Determine Provectus Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Provectus Biopharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Provectus Biopharmaceutica Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Provectus Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 419.4 M | |
| Retained Earnings | -246 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |